

Amendments to the Claims:

This claim listing will replace all prior versions and listings of claims in the application:

Claim Listing

1. (Currently Amended) A method for inhibiting the expression of human DNA methyltransferase-1 in a cell comprising contacting the cell with an effective synergistic amount of an antisense oligonucleotide which inhibits expression of the DNA methyltransferase-1 gene, and an effective synergistic amount of a protein effector of human DNA methyltransferase-1.
2. (Currently Amended) A method for treating a disease responsive to inhibition of human DNA methyltransferase-1 gene comprising administering to a human, which has at least one cell affected by the disease present in its body, a therapeutically effective synergistic amount of an antisense oligonucleotide which inhibits expression of the human DNA methyltransferase-1 gene, and a therapeutically effective synergistic amount of a protein effector of human DNA methyltransferase-1.
3. (Currently Amended) A method for inhibiting tumor growth in a human comprising administering to a human, which has at least one neoplastic cell in its body, a therapeutically effective synergistic amount of an antisense oligonucleotide which inhibits expression of the human DNA methyltransferase-1 gene and a therapeutically effective synergistic amount of a protein effector of human DNA methyltransferase-1.
4. CANCELED
5. CANCELED
6. (Previously Amended) The method of claim 1, 2 or 3, wherein the protein effector is selected from the group consisting of 5-aza-cytidine and 5-aza-2'-deoxycytidine.
7. CANCELED
8. CANCELED

9. CANCELED

10. CANCELED

11. CANCELED.

12. CANCELED.

13. (Original) The method of claim 1, 2 or 3, wherein the antisense oligonucleotide comprises a ribonucleotide or 2'-O-substituted ribonucleotide region and a deoxyribonucleotide region.

14-50 CANCELED